TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03665896

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intubation with VivaSight double-lumen tube

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: intubation with standard double-lumen tube

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: fiberoptic bronchoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fiberoptic bronchoscopy
Study: NCT02909270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mediclore
Description: to apply mediclore fully around thyroid gland
Study: NCT00792805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 µg
Description: Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Description: Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
Study: NCT04586517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy-load resistance training
Description: Supervised heavy-load resistance training during chemotherapy treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Activity as usual during chemotherapy
Study: NCT03096366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
Study: NCT03450798

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOFT block group
Description: needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: spinal anesthesia group
Description: patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.
Study: NCT01727622

Intervention type: DRUG
Intervention: FDG-PET
Description: Diagnostic: FDG-PET imaging to examine neuronal health

Intervention type: DRUG
Intervention: FDG-PET
Description: Diagnostic: FDG-PET imaging to examine neuronal health

Intervention type: OTHER
Intervention: ASL-MRI
Description: Arterial-Spin Labeled MRI to examine cerebral blood flow

Intervention type: OTHER
Intervention: ASL-MRI
Description: Arterial-Spin Labeled MRI to examine cerebral blood flow

Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Lumbar puncture to acquire a small amount of cerebrospinal fluid for protein level analyses. Note that this will not be required in all participants.

Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Lumbar puncture to acquire a small amount of cerebrospinal fluid for protein level analyses. Note that this will not be required in all participants.
Study: NCT02808143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Solution
Description: Given intravesically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given intravesically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02721745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Natural Fatigue
Description: Experimental: EEG Indirect Calorimetry Pupillometry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Experimental: EEG Indirect Calorimetry Pupillometry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Experimental: EEG Indirect Calorimetry Pupillometry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Experimental: EEG Indirect Calorimetry Pupillometry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Experimental: EEG Indirect Calorimetry Pupillometry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Experimental: EEG Indirect Calorimetry Pupillometry
Study: NCT01177787

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zeltiq
Description: Cryolipolysis had been conducted for targeted fat area on thigh for 1 hour through Zeltiq machine made in Zeltiq Aesthetics.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: electrical stimulation
Description: Lipolysis would be done on controlateral thigh for 30 minutes through 3000 Hz- amplitude modulated frequency.
Study: NCT02598752

Intervention type: OTHER
Intervention: Symptom-limited cardiopulmonary exercise test (CPET)

Intervention type: OTHER
Intervention: Resting assessment of cardiac function by echocardiography

Intervention type: OTHER
Intervention: Post-exercise assessment of cardiac function by echocardiography

Intervention type: OTHER
Intervention: Pulmonary function

Intervention type: BEHAVIORAL
Intervention: Patient-reported outcomes questionnaire
Study: NCT03265834

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: < 10 days of antibiotics
Description: Antibiotic duration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 28 days of antibiotics
Description: Antibiotic duration
Study: NCT02711488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The proposed intervention will focus on encouraging students to change their eating habits and food consumption over 9 months (from March to November). Monthly 1-h sessions in the classroom will be given by the class teacher, and includes playing games, staging theater sketches, watching movies and puppet shows, and writing and drawing contests. The activities were designed to discourage students from consuming sugar-sweetened beverages as well as getting them to replace snacks, particularly processed foods (especially cookies) with fresh fruit or healthy homemade food. To reinforce the messages of the in-class nutritional sessions, a set of messages will be sent to the families in the form of illustrated booklets and recipes.~The secondary prevention strategy at households will be developed for those with excessive weight. The family will receive additional motivation to change these behaviors, using the community health agents as the encourager.
Study: NCT02170454

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: magnetic stimulation
Description: rTMS on pharyngeal cortical area in healthy subjects or sham rTMS on pharyngeal cortical area in healthy subjects

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: magnetic stimulation
Description: rTMS on pharyngeal cortical area in healthy subjects or sham rTMS on pharyngeal cortical area in healthy subjects
Study: NCT01410136

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chondrofix Osteochondral Allograft
Description: Allogeneic, cylindrical, decellularized, osteochondral graft composed of hyaline cartilage and bone
Study: NCT02090374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Dose escalation: 10ug, 100ug, 500ug Highest dose: 1000ug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Dose escalation: 10ug, 100ug, 500ug Highest dose: 1000ug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Poly I:C
Description: Single dose: 500ug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: R848
Description: High dose: 10ug Low dose: 1-2ug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: R848
Description: High dose: 10ug Low dose: 1-2ug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timothy Grass Pollen
Description: Dose: 5000 SQ-U/100µl

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 4000U orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuberculin
Description: Tuberculin PPD
Study: NCT01480674

Intervention type: DRUG
Intervention: Trastuzumab
Study: NCT03404765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Study: NCT02689596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00309556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 6 cycles 75mg/m2 i.v. day 1 q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 6 cycles 75mg/m2 i.v. day 1 q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 6 cycles 75mg/m2 i.v. day 1 q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 6 cycles 75mg/m2 i.v. day 1 q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 6 cycles 1000mg/m2 oral, day 1-14 q2d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: cycle 1: 8mg/kg i.v. day 1 cycle 2-6: 6mg/kg i.v. day 1 (=6 cycles q3w)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: cycle 1: 8mg/kg i.v. day 1 cycle 2-6: 6mg/kg i.v. day 1 (=6 cycles q3w)
Study: NCT00786825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatostatin
Description: Somatostatin may be used to suppress endogenous insulin secretion
Study: NCT04615247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Program
Description: The yoga program is designed to maximize women's awareness of and control over the pelvic floor, promote relaxation, and improve physical function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Conditioning Program
Description: The physical conditioning program will focus on a core set of exercises designed to improve physical function and emotional well-being in order to improve management of chronic pain.
Study: NCT04577196

Intervention type: OTHER
Intervention: Trauma dashboard
Description: A large dashboard available to all, providing a framework for synthesizing and displaying relevant information about the arriving critical patient, to be filled in by the trauma leader.
Study: NCT03400332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT04291352

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taurine
Description: 675mg taurine four times daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo four times daily
Study: NCT01942720

Intervention type: DEVICE
Group type: OTHER
Intervention: Capsule endoscopy and Ileocolonoscopy tests
Study: NCT02013505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: An educational video was developed based on the current paper instructions for bowel preparation. The video included a physician explaining the process, using more images and short clip videos of the example. The script of the video was approved by the patient education department of the University Hospital and language adjusted to 6th grade level.
Study: NCT03064386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plate fixation
Description: internal fixation with the plate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screw fixation
Description: internal fixation with the screw
Study: NCT02277405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shikani Optical Stylet
Description: Optical intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shikani Optical Stylet
Description: Optical intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoeye Flexible Intubation (LF-V)
Description: endoscopy intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoeye Flexible Intubation (LF-V)
Description: endoscopy intubation
Study: NCT03537287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17 alpha hydroxyprogestrone caproate
Description: 250 mg of 17 alpha hydroxyprogestrone caproate weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone
Description: 200 mg of vaginal progesterone daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral dydrogesterone
Description: 2 tablets of dydrogesterone daily
Study: NCT03525899

Intervention type: PROCEDURE
Intervention: Pars plana vitrectomy
Description: Pars plana vitrectomy combined with Internal limiting membrane peeling, inverted internal limiting membrane flap insertion into the macular hole, or lens anterior or posterior capsular flap insertion into the macular hole
Study: NCT02031289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
Description: Treatment ) will be given the day before the operation (day -1) or a maximum of 2 days prior to the operation (day -2) in iron deficiency patients and a maximum of 3 days prior to the operation in anemic patients (day -3).~Erythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc. Ferric carboxymaltose (Ferinject, Vifor (International) AG, St. Gallen) 1000 mg in 100 ml NaCl over 30 min.~Vitamin B12 (Vitarubin®-superconc., Streuli Pharma AG, Uznach) 1 mg sc. Folic acid (Acidum folicum, Streuli Pharma AG, Uznach) 5 mg po.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
Description: Treatment ) will be given the day before the operation (day -1) or a maximum of 2 days prior to the operation (day -2) in iron deficiency patients and a maximum of 3 days prior to the operation in anemic patients (day -3).~Erythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc. Ferric carboxymaltose (Ferinject, Vifor (International) AG, St. Gallen) 1000 mg in 100 ml NaCl over 30 min.~Vitamin B12 (Vitarubin®-superconc., Streuli Pharma AG, Uznach) 1 mg sc. Folic acid (Acidum folicum, Streuli Pharma AG, Uznach) 5 mg po.
Study: NCT00151957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Transdermal System
Description: MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
Study: NCT02842840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-based intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family based intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine counseling
Study: NCT01054651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate+Sulfamethoxypyrazine/pyrimethamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel
Study: NCT02088749

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle intervention for obesity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention for obesity
Study: NCT02215538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo medication appears identical to the active medication OROS methylphenidate
Study: NCT02579174

Intervention type: DEVICE
Group type: OTHER
Intervention: Medacta GMK Sphere

Intervention type: DEVICE
Group type: OTHER
Intervention: Medacta GMK Sphere

Intervention type: DEVICE
Group type: OTHER
Intervention: Medacta GMK Sphere

Intervention type: DEVICE
Group type: OTHER
Intervention: Medacta GMK Sphere
Study: NCT01319214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inderal
Description: Inderal vs. placebo will be administered with or without cocaine cues

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inderal
Description: Inderal vs. placebo will be administered with or without cocaine cues

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inderal
Description: Inderal vs. placebo will be administered with or without cocaine cues

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inderal
Description: Inderal vs. placebo will be administered with or without cocaine cues
Study: NCT00683176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choline Fenofibrate
Description: 135 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02272855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HF10 plus Ipilimumab
Description: Patients will receive the dose of 1 x 10\^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
Study: NCT01596907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine sulfate with caffeine
Description: Ephedrine sulfate 25-mg with caffeine 200-mg combination capsule to start 5 weeks after gastric bypass surgery at 3 times per day 4 hours apart.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cellulose
Description: sufficient cellulose to fill a placebo capsule identical to the active drug to be taken 3 times per day 4 hours apart for 6 months after gastric bypass surgery
Study: NCT02361138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00830648

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Varicella Virus Vaccine
Description: 0.5 mL, Subcutaneous
Study: NCT03289377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RDAD Training
Description: An interactive processes of lecture, role-play, and discussion, APNs will have the opportunity to dissect all phases of RDAD to insure they understand the objectives, can enact the program, and feel confident they can problem-solve situations that arise. APNs will receive materials to insure they are knowledgeable about ADRD symptoms, behavior management techniques, and exercise safety.
Study: NCT03673865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: office-based 3-dimensional printers (OB3DP)
Description: In this treatment group subjects, using office-based 3-dimensional printers (OB3DP) a patient-specific pre-adjusted (pre-bend) orbital plates will be made using over-the-counter titanium plates that are manually adjusted according to the printed model. The plates are then send to sterilization for preparation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard stock orbital plate
Description: In this control group subjects will receive non-patient-specific orbital implants which is standard stock orbital plate that is adapted intraoperatively to the fractured orbit
Study: NCT00945308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eptifibatide
Description: Intracoronary injection of Eptifibatide injected in two consecutive bolus of 180 mcg/kg each, followed immediately by continuous infusion of 2 mcg/kg/min for 12 hs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eptifibatide
Description: Intravenous injection of Eptifibatide in two consecutive boluses of 180 mcg/kg followed by continuous intravenous injection dosing 2 mcg/kg/min for 12 hours
Study: NCT00935194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir
Description: 75mg,bid,for 5 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blank
Description: no antiviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chinese medicinal herbs
Description: 200ml,p.o,qid,for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir and chinese medicinal herbs
Description: oseltamivir:75mg,p.o,bid,for 5 days; chinese medicinal herbs:200ml,p.o,qid,for 5 days